Overview

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.

Phase:

Phase 2

Details

Lead Sponsor:

Kastle Therapeutics, LLC

Collaborator:

Ionis Pharmaceuticals, Inc.

Treatments:

Mipomersen